Glioma Market: Epidemiology, Therapies, Companies | DelveInsight | Key players in the glioma market include Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, AnHeart Therapeuti

According to DelveInsight estimates, in 2023, the United States accounted for the highest Glioma market size, i.e. approximately USD 650 million.

Emerging therapies such as ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others are expected to drive growth in the glioma market over the coming years.

DelveInsight has released a new report titled "Glioma - Market Insights, Epidemiology, and Market Forecast 2034," providing a detailed analysis of glioma, including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Glioma market report @ https://www.delveinsight.com/report-store/glioma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Glioma Market Report:

*
According to DelveInsight estimates, the United States accounted for the largest glioma market in 2023, valued at approximately USD 650 million. Current standard treatments for glioma-including surgery, radiation, temozolomide, and maintenance temozolomide therapy-are largely ineffective, with 95% of patients experiencing relapse.

*
In February 2025, the FDA accepted a new drug application (NDA) for the accelerated approval of dordaviprone (ONC201; Chimerix) for the treatment of recurrent H3 K27M-mutant diffuse glioma. In January 2025, Chimerix submitted the NDA requesting priority review with a target action date set for Q3 2025 under the PDUFA program. Dordaviprone has also received rare pediatric disease designation for this indication.

*
In 2023, the United States accounted for the largest share of glioma cases, representing about 40% of the total in the 7MM. Within the EU4 and the UK, Germany had the highest number of glioma cases, followed by France, while Spain reported the fewest cases.

*
FDA-approved therapies for glioma include OPTUNE (Novocure), AVASTIN (Genentech), TEMODAR (Merck), and the combination TAFINLAR + MEKINIST (Novartis). The FDA approved the bevacizumab biosimilar ZIRABEV (Pfizer) in June 2019 for the same indications as AVASTIN, following bevacizumab-awwb (MVASI; Amgen) in 2017. These biosimilars are expected to reduce AVASTIN's market share due to lower treatment costs.

*
In October 2023, the FDA accepted the NDA for tovorafenib monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG), granting it priority review with a PDUFA date of April 30, 2024.

*
The glioma market is expected to grow substantially due to promising results from several developmental-stage products, including AV-GBM-1, ITI-1000, LAM561, DCVax-L, INO-5401+, INO-9012 + LIBTAYO, SurVaxM, Enzastaurin Hydrochloride, VAL-083, temferon, DAY101, vorasidenib, and others.

*
The recent label expansion of Novartis' TAFINLAR (dabrafenib) + MEKINIST (trametinib) to treat pediatric patients aged one year and older with low-grade glioma harboring the BRAF V600E mutation broadens commercial opportunities. However, the limited number of approved therapies for low-grade glioma highlights a significant opportunity for new drug development in this segment.

*
Key glioma companies, including Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, AnHeart Therapeutics, Plus Therapeutics, Basilea Pharmaceutica, BeiGene, Kazia Therapeutics, AstraZeneca, Nerviano Medical Sciences, VBL Therapeutics, Philogen S.p.A., Xennials Therapeutics, Laminar Pharmaceutical, and others, are actively evaluating new drugs to improve the treatment landscape.

*
Promising glioma therapies include ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others.

Glioma Overview

Glioma is the most prevalent type of central nervous system (CNS) tumor, arising from glial cells. These tumors are highly invasive, often spreading extensively into surrounding brain tissue. Gliomas are typically classified into three main categories based on cellular characteristics: astrocytomas, ependymomas, and oligodendrogliomas. They develop as a result of genetic mutations accumulating in glial stem or progenitor cells, leading to uncontrolled cell proliferation. Gliomas are graded from I to IV, with glioblastoma (GBM, Grade IV) representing the most aggressive form, and pilocytic astrocytomas (Grade I) being the least malignant. Frequently mutated genes in gliomas include tumor suppressors such as TP53 and PTEN, growth-related genes like BRAF, and metabolism-associated genes including IDH1.

Glioma Market Outlook

Gliomas are graded into four categories based on their degree of differentiation, with Grade I being the most differentiated and least aggressive, and Grade IV the least differentiated and most malignant. Managing gliomas requires a multidisciplinary team of medical specialists due to the complexity of the disease. Treatment is challenging because some tumor cells respond to therapy while others may remain resistant. Consequently, glioma management often involves a combination of approaches, including surgery, chemotherapy, radiation, or stereotactic radiosurgery, followed by adjuvant therapies such as chemotherapy or radiation after surgery.

The first line of treatment is typically surgery, aimed at diagnosis, relieving intracranial pressure, and removing as much of the tumor as safely possible. The objective is to perform a "maximum safe resection," removing the largest amount of tumor tissue without causing permanent neurological damage.

From a commercial perspective, high-grade gliomas receive greater attention than low-grade gliomas, as patients with low-grade tumors generally have longer survival. Consequently, only a limited number of therapies for low-grade gliomas are in late-stage development, with most in early-phase trials. In contrast, the glioblastoma (GBM) pipeline is extensive, featuring multiple promising drugs in mid- and late-stage development that are yet to be launched. These candidates utilize diverse mechanisms of action and delivery methods.

Notably, the emerging glioma market includes innovative gene therapies such as ofranergene obadenovec (VB-111) by VBL Therapeutics, along with vaccine and immunotherapy candidates like VBI-1901, AV-GBM-1, ITI-1000 (pp65 DC Vaccine), and tasadenoturev (DNX-2401). These therapies, developed by companies including VBI Vaccines, AIVITA Biomedical, Immunomic Therapeutics, and DNAtrix, are expected to significantly influence the glioma market in the coming years.

Discover how the Glioma market is rising in the coming years @ https://www.delveinsight.com/sample-request/glioma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Glioma Marketed Drugs

*
AVASTIN: Genentech

*
TEMODAR (temozolomide): Merck

Glioma Emerging Drugs

*
Ofranergene obadenovec (VB-111): VBL Therapeutics

*
SurVaxM: MimiVax

*
Vorasidenib (AG-881): Servier

*
Tovorafenib (DAY101): Day One Biopharmaceuticals

Scope of the Glioma Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Glioma Companies: Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, AnHeart Therapeutics, Plus Therapeutics, Basilea Pharmaceutica, BeiGene, Kazia Therapeutics, AstraZeneca, Nerviano Medical Sciences, VBL Therapeutics, Philogen S.p.A., Xennials Therapeutics, Laminar Pharmaceutical, and others

*
Glioma Therapies: ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and others.

*
Glioma Therapeutic Assessment: Glioma current marketed and Glioma emerging therapies

*
Glioma Market Dynamics: Glioma market drivers and Glioma market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Glioma Unmet Needs, KOL's views, Analyst's views, Glioma Market Access and Reimbursement

To know what's more in our Glioma report, visit https://www.delveinsight.com/report-store/glioma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Glioma Market Report:

*
Glioma market report covers a descriptive overview and comprehensive insight of the Glioma Epidemiology and Glioma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Glioma market report provides insights into the current and emerging therapies.

*
The Glioma market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Glioma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Glioma market.

Got queries? Click here to know more about the Glioma market Landscape [https://www.delveinsight.com/sample-request/glioma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Glioma Patient Share (%) Overview at a Glance

5. Glioma Market Overview at a Glance

6. Glioma Disease Background and Overview

7. Glioma Epidemiology and Patient Population

8. Country-Specific Patient Population of Glioma

9. Glioma Current Treatment and Medical Practices

10. Unmet Needs

11. Glioma Emerging Therapies

12. Glioma Market Outlook

13. Country-Wise Glioma Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Glioma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Glioma Market Outlook 2034 [https://www.delveinsight.com/report-store/glioma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Glioma Pipeline Insights, DelveInsight

"Glioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Glioma market. A detailed picture of the Glioma pipeline landscape is provided, which includes the disease overview and Glioma treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioma-market-epidemiology-therapies-companies-delveinsight-key-players-in-the-glioma-market-include-chimerix-sumitomo-dainippon-pharma-aivita-biomedical-denovo-biopharma-anheart-therapeuti]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.